Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04154800 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
NCT04154800 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 114 participants.
The verdict
NCT04154800, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
Interventions
- DRUG Itraconazole
- DRUG Diltiazem
- DRUG BMS-986209
- OTHER BMS-986209 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2019-12-06 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04154800
The ClinicalTrials.gov registry entry for NCT04154800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 114 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Itraconazole is the first listed.
NCT04154800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04154800 about?
NCT04154800 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants". The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
What is the current status of trial NCT04154800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2019-12-06. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT04154800?
The interventions under investigation include: Itraconazole (DRUG), Diltiazem (DRUG), BMS-986209 (DRUG), BMS-986209 Placebo (OTHER).
Who is sponsoring clinical trial NCT04154800?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.